Abstract: Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 ?m which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.

Abstract: Subjects of the invention are a method of plasminogen supplementation in a plasminogen-deficient subject, and method for the treatment of plasminogen-deficiency in a plasminogen-deficient subject. These methods comprise administering to the plasminogen-deficient subject a dose of plasminogen, and more particularly Glu-plasminogen, for increasing the subject plasminogen activity level by at least about 1%, and more particularly by at least 10%, of the normal plasminogen activity and for maintaining the plasminogen activity level over a supplementation period or a treatment period. The plasminogen-deficient subject of the present invention may suffer from Type-I, Type-II plasminogen-deficiency or an acquired deficiency.

Abstract: The present invention discloses a method and process to laminate packaging substrates using an adhesive tape. The tape has a first heat activated adhesive which is activatable at a first temperature and a second heat activated adhesive which is activatable at a second temperature and both of which are alternatively coated on at least one surface of the tape. The method consists of laminating this aforementioned tape to a packaging substrate by following the process of: placing this tape in or on a laminating machine over the packaging substrate, heating the tape at least to the second temperature while making contact with the packaging substrate, cooling the packaging laminate until the second heat activated adhesive is set and cutting a predetermined portion of the packaging laminate before a second adhesive occurs between the tape and the packaging laminate.

Abstract: Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 ?m which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.

Abstract: Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 ?m which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.

Abstract: The present invention discloses a method and process to laminate packaging substrates using an adhesive tape. The tape has a first heat activated adhesive which is activatable at a first temperature and a second heat activated adhesive which is activatable at a second temperature and both of which are alternatively coated on at least one surface of the tape. The method consists of laminating this aforementioned tape to a packaging substrate by following the process of: placing this tape in or on a laminating machine over the packaging substrate, heating the tape while making contact with the packaging substrate, cooling the packaging laminate until the first heat activated adhesive is set and cutting a predetermined portion of the packaging laminate before a second adhesive occurs between the tape and the packaging laminate.

Abstract: Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 ?m which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.

Abstract: Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilizing agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 ?m which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.

Abstract: Subjects of the invention are a method of plasminogen supplementation in a plasminogen-deficient subject, and method for the treatment of plasminogen-deficiency in a plasminogen-deficient subject. These methods comprise administering to the plasminogen-deficient subject a dose of plasminogen, and more particularly Glu-plasminogen, for increasing the subject plasminogen activity level by at least about 1%, and more particularly by at least about 10%, of the normal plasminogen activity and for maintaining said increased plasminogen activity level over a supplementation period or a treatment period. The plasminogen-deficient subject of the present invention may suffer from Type-I, Type-II plasminogen-deficiency or an acquired deficiency.

Abstract: The invention concerns the use of plasminogen or a biologically active variant thereof for the preparation of a medicament for local administration of at least one dose of plasminogen or a biologically active variant thereof for promoting the healing of a wound in a subject. The dose is between about 2 mg and about 30 mg. The frequency of the administration may vary from once a day to once a week. The invention further concerns the related medicaments and methods of treatment.

Abstract: Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 ?m which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.

Abstract: An adhesive packaging system, such as a tape or a string, and laminating methods are disclosed. The system comprises a core structure and an adhesive layer coated at least on one surface defined by the core structure. The adhesive layer comprises at least two different heat-activated adhesive materials in alternative sequences over the surface of the core structure, the heat-activated adhesive materials being activated at different temperatures. As the tapes are processed in the laminating machines, some of the adhesives will be heat activated with enough operating range that the tapes will have the proper adhesion to the substrate in any operating conditions, and some of the adhesives will set at the exit of the laminating machines also at any operating conditions of the laminating machines. Hence the tapes will have a much larger operating envelope under a very large range of operating conditions in the laminating machines.

Abstract: A modular stair tread overlay including a tread and a front nosing attached to a front edge of the tread cover is disclosed. The front nosing is attached to a front edge by a securing means such as a tongue and groove joint to providing a strong mechanical joint between the nosing portions and the tread cover. Adhesive may be applied at the tongue and groove joint to enhance the strength of the joint. The front nosing of the modular stair tread is hollow thereby allowing the installation of the stair tread overlay over the original stairs without the requirement of removing or trimming the nose of the original stair treads. The stair tread and the nosing can also be unitary and be made of material such as metal, plastic or composite. A method for remodeling stair sets is also disclosed.

Abstract: The present invention discloses an open air dryer having one or more layers of flexible clothes dryers. Each clothes dryer is made of at least one generally rectangular piece of breathable fabric or net like material mounted on two parallel support bars made of a rigid material. The length of each layer is fully adjustable. Each support bar is held by at least one hook and preferably two hooks to any external structures such as walls, dryer, washer or other self-supporting structure.

Abstract: The present invention is concerned with This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

Abstract: The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.

Abstract: The present invention discloses a roll holder for tape dispenser and a tape dispenser assembly therewith. The roll holder comprises a cylindrical body and an annular portion made from a material having a high friction coefficient, the annular portion being fixed inside the cylindrical body. The roll holder tape dispenser is supported by a shaft. Two cylindrical bodies are connected to a roll of tape, one at each extremity of the tape spool by press-fitting. The shaft passes through the annular portion and the friction occurring between the shaft and annular portion induce a tension in the tape when the tape is unwound from the roll.

Abstract: The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

Abstract: This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.

Abstract: The present invention discloses a roll holder for tape dispenser and a tape dispenser assembly therewith. The roll holder comprises a cylindrical body and an annular portion made from a material having a high friction coefficient, the annular portion being fixed inside the cylindrical body. The roll holder tape dispenser is supported by a shaft. Two cylindrical bodies are connected to a roll of tape, one at each extremity of the tape spool by press-fitting. The shaft passes through the annular portion and the friction occurring between the shaft and annular portion induce a tension in the tape when the tape is unwound from the roll.